bioAffinity Technologies, Inc. (BIAF)
2.15
+0.22
(+11.40%)
USD |
NASDAQ |
Nov 18, 16:00
2.08
-0.07
(-3.26%)
After-Hours: 20:00
bioAffinity Technologies Debt to Equity Ratio : 0.3827 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.3827 |
| June 30, 2026 | 0.3808 |
| March 31, 2026 | 0.3776 |
| December 31, 2025 | 0.1595 |
| September 30, 2025 | 0.0765 |
| June 30, 2025 | -0.3137 |
| March 31, 2025 | 0.9248 |
| December 31, 2024 | 0.5769 |
| September 30, 2024 | 0.5509 |
| June 30, 2024 | 0.402 |
| March 31, 2024 | 0.2843 |
| December 31, 2023 | 0.3251 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.2411 |
| June 30, 2023 | 0.0052 |
| March 31, 2023 | 0.0174 |
| December 31, 2022 | 0.0228 |
| September 30, 2022 | 0.0647 |
| June 30, 2022 | -0.8729 |
| March 31, 2022 | -0.9405 |
| December 31, 2021 | -0.9675 |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | -0.9073 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Anika Therapeutics, Inc. | 0.1901 |
| Perspective Therapeutics, Inc. | 0.0125 |
| MiMedx Group, Inc. | 0.00 |
| Veracyte, Inc. | 0.0284 |
| T2 Biosystems, Inc. | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 7.554M |
| Total Liabilities (Quarterly) | 3.639M |
| Shareholders Equity (Quarterly) | 3.915M |
| Current Ratio | 1.511 |
| Net Debt Paydown Yield | -2.16% |